McKesson MCK has started 2025 on a positive note, with the stock climbing 4% so far in January as investors remain optimistic ...

Shares of McKesson Corp. MCK slipped 1.10% to $586.08 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.88% to 6,049.24 and ...

The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 10.2% in ...

McKesson's stock appears undervalued, trading at 18 times forward earnings and free cash flow. See why MCK is a Hold.

Evercore ISI analyst Elizabeth Anderson CFA reiterated a Buy rating on McKesson (MCK – Research Report) yesterday and set a price target of ...

Texas-based McKesson Corporation (MCK) is a global healthcare services and information technology company. Operating through four key segments - U.S. Pharmaceutical; Prescription Technology ...

McKesson has launched McKesson Amplify, a strategic initiative intended to help protect critical pharmacy services and elevate the pharmacy profession by strengthening the voice of the ...

AdvisorNet Financial Inc lessened its holdings in McKesson Co. (NYSE:MCK – Free Report) by 11.8% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional ...

Joe DePinto, MBA, discussed the findings of the McKesson 2024 Cell and Gene Therapy Report, providing insight into the ...

Beyond funding, McKesson Amplify also will provide resources, strategic support and other tools to help state pharmacy associations achieve their local and state advocacy goals in 2025.

McKesson Corporation (MCK ... of growth from GLP-1 medications and a robust oncology network business. Vertex Pharmaceuticals (VRTX) comes in second with a score of 4.04 and a Buy rating given ...